Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Link to record
Permanent link

Direct link
Alternative names
Publications (10 of 50) Show all publications
Karlsson, L., Cheuk, D., De Moerloose, B., Hasle, H., Jahnukainen, K., Juul-Dam, K. L., . . . Abrahamsson, J. (2023). Characteristics and outcome of primary resistant disease in paediatric acute myeloid leukaemia. British Journal of Haematology, 201(4), 757-765
Open this publication in new window or tab >>Characteristics and outcome of primary resistant disease in paediatric acute myeloid leukaemia
Show others...
2023 (English)In: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 201, no 4, p. 757-765Article in journal (Refereed) Published
Abstract [en]

A significant proportion of events in paediatric acute myeloid leukaemia (AML) are caused by resistant disease (RD). We investigated clinical and biological characteristics in 66 patients with RD from 1013 children with AML registered and treated according to the NOPHO-AML 93, NOPHO-AML 2004, DB AML-01 and NOPHO-DBH AML 2012 protocols. Risk factors for RD were age10 years or older and a white-blood-cell count (WBC) of 100 x 10(9)/L or more at diagnosis. The five-year overall survival (OS) was 38% (95% confidence interval [CI]: 28%-52%). Of the 63 children that received salvage therapy with chemotherapy, 59% (N = 37) achieved complete remission (CR) with OS 57% (95% CI: 42%-75%) compared to 12% (95% CI: 4%-35%) for children that did not achieve CR. Giving more than two salvage chemotherapy courses did not increase CR rates. OS for all 43 patients receiving allogeneic haematopoietic stem cell transplantation (HSCT) was 49% (95% CI: 36%-66%). Those achieving CR and proceeding to HSCT had an OS of 56% (95% CI: 41%-77%, N = 30). This study showed that almost 40% of children with primary resistant AML can be cured with salvage therapy followed by HSCT. Children that did not achieve CR after two salvage courses with chemotherapy did not benefit from additional chemotherapy.

Place, publisher, year, edition, pages
John Wiley & Sons, 2023
Keywords
acute myeloid leukaemia, paediatric, resistant disease, survival
National Category
Pediatrics Hematology Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-512788 (URN)10.1111/bjh.18685 (DOI)000931412000001 ()36762836 (PubMedID)
Available from: 2023-10-03 Created: 2023-10-03 Last updated: 2023-10-03Bibliographically approved
Stratmann, S., Vesterlund, M., Umer, H. M., Skaftason, A., Herlin, M. K., Sundström, C., . . . Holmfeldt, L. (2023). Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children. Leukemia, 37(3), 550-559
Open this publication in new window or tab >>Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children
Show others...
2023 (English)In: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 37, no 3, p. 550-559Article in journal (Refereed) Published
Abstract [en]

Despite improvement of current treatment strategies and novel targeted drugs, relapse and treatment resistance largely determine the outcome for acute myeloid leukemia (AML) patients. To identify the underlying molecular characteristics, numerous studies have been aimed to decipher the genomic- and transcriptomic landscape of AML. Nevertheless, further molecular changes allowing malignant cells to escape treatment remain to be elucidated. Mass spectrometry is a powerful tool enabling detailed insights into proteomic changes that could explain AML relapse and resistance. Here, we investigated AML samples from 47 adult and 22 pediatric patients at serial time-points during disease progression using mass spectrometry-based in-depth proteomics. We show that the proteomic profile at relapse is enriched for mitochondrial ribosomal proteins and subunits of the respiratory chain complex, indicative of reprogrammed energy metabolism from diagnosis to relapse. Further, higher levels of granzymes and lower levels of the anti-inflammatory protein CR1/CD35 suggest an inflammatory signature promoting disease progression. Finally, through a proteogenomic approach, we detected novel peptides, which present a promising repertoire in the search for biomarkers and tumor-specific druggable targets. Altogether, this study highlights the importance of proteomic studies in holistic approaches to improve treatment and survival of AML patients.

Place, publisher, year, edition, pages
Springer Nature, 2023
Keywords
Acute myeloid leukemia, proteomics, proteogenomics, relapse and resistance
National Category
Cancer and Oncology Hematology
Research subject
Biology with specialization in Molecular Biology
Identifiers
urn:nbn:se:uu:diva-427205 (URN)10.1038/s41375-022-01796-7 (DOI)000903999000001 ()36572751 (PubMedID)
Funder
Swedish Research Council, 2018-05973Swedish Research Council, 2013-03486Knut and Alice Wallenberg Foundation, 2013-03486Swedish Childhood Cancer Foundation, PR2013-0070Swedish Childhood Cancer Foundation, TJ2013-0045Swedish Cancer Society, CAN2013/489Kjell and Marta Beijer Foundation
Note

Title in the list of papers of Svea Stratmann thesis: Proteogenomic analysis of relapsed acute myeloid leukemia in adults and children

Authors in the list of papers of Svea Stramann: S. Stratmann, M. Vesterlund, H.M. Umer, A. Skaftason, M. Krogh Herlin, C. Sundström, A. Eriksson, M. Höglund, J. Palle, J. Abrahamson, K. Jahnukainen, M. Cheng Munthe-Kaas, B. Zeller, K. Pokrovskaja Tamm, L. Cavelier, J. Lehtiö, L. Holmfeld

Available from: 2020-12-03 Created: 2020-12-03 Last updated: 2023-05-12Bibliographically approved
Berglund, E. C., Barbany, G., Orsmark-Pietras, C., Fogelstrand, L., Abrahamsson, J., Golovleva, I., . . . Rosenquist, R. (2022). A Study Protocol for Validation and Implementation of Whole-Genome and -Transcriptome Sequencing as a Comprehensive Precision Diagnostic Test in Acute Leukemias. Frontiers in Medicine, 9, Article ID 842507.
Open this publication in new window or tab >>A Study Protocol for Validation and Implementation of Whole-Genome and -Transcriptome Sequencing as a Comprehensive Precision Diagnostic Test in Acute Leukemias
Show others...
2022 (English)In: Frontiers in Medicine, E-ISSN 2296-858X, Vol. 9, article id 842507Article in journal (Refereed) Published
Abstract [en]

Background:& nbsp;Whole-genome sequencing (WGS) and whole-transcriptome sequencing (WTS), with the ability to provide comprehensive genomic information, have become the focal point of research interest as novel techniques that can support precision diagnostics in routine clinical care of patients with various cancer types, including hematological malignancies. This national multi-center study, led by Genomic Medicine Sweden, aims to evaluate whether combined application of WGS and WTS (WGTS) is technically feasible and can be implemented as an efficient diagnostic tool in patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). In addition to clinical impact assessment, a health-economic evaluation of such strategy will be performed.& nbsp.

Methods and Analysis:& nbsp;The study comprises four phases (i.e., retrospective, prospective, real-time validation, and follow-up) including approximately 700 adult and pediatric Swedish AML and ALL patients. Results of WGS for tumor (90x) and normal/germline (30x) samples as well as WTS for tumors only will be compared to current standard of care diagnostics. Primary study endpoints are diagnostic efficiency and improved diagnostic yield. Secondary endpoints are technical and clinical feasibility for routine implementation, clinical utility, and health-economic impact.& nbsp.

Discussion:& nbsp;Data from this national multi-center study will be used to evaluate clinical performance of the integrated WGTS diagnostic workflow compared with standard of care. The study will also elucidate clinical and health-economic impacts of a combined WGTS strategy when implemented in routine clinical care.

Place, publisher, year, edition, pages
Frontiers Media S.A.Frontiers Media SA, 2022
Keywords
acute lymphoblastic leukemia, acute myeloid leukemia, whole-genome sequencing, whole-transcriptome sequencing, technical feasibility, clinical utility, health-economic evaluation
National Category
Hematology
Identifiers
urn:nbn:se:uu:diva-475123 (URN)10.3389/fmed.2022.842507 (DOI)000789699000001 ()35402448 (PubMedID)
Funder
Swedish Cancer SocietySwedish Research CouncilKarolinska Institute
Available from: 2022-05-31 Created: 2022-05-31 Last updated: 2024-01-15Bibliographically approved
Borgstedt-Bendixen, S. E., Abrahamsson, J., Ha, S.-Y., Koskenvuo, M., Lausen, B., Palle, J., . . . Lohmann, D. J. A. (2022). Abdominal Complications During Treatment for Pediatric Acute Myeloid Leukemia. Journal of Pediatric Hematology/Oncology, 44(5), 220-229
Open this publication in new window or tab >>Abdominal Complications During Treatment for Pediatric Acute Myeloid Leukemia
Show others...
2022 (English)In: Journal of Pediatric Hematology/Oncology, ISSN 1077-4114, E-ISSN 1536-3678, Vol. 44, no 5, p. 220-229Article in journal (Refereed) Published
Abstract [en]

Acute myeloid leukemia (AML) accounts for 15% to 20% of childhood leukemias. Because of high-intensive therapy, up to 5% of patients suffer from treatment-related mortality (TRM). Abdominal complications are frequent, however, literature on this subject is sparse. We aimed to characterize severe abdominal pain (AP) and hyperbilirubinemia experienced by pediatric AML patients treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO)-AML 2004 protocol (n=313). Patients were censored at hematopoietic stem cell transplantation and relapse. Toxicity information was collected prospectively. Additional information was requested retrospectively from the treating centers. Sixteen episodes of hyperbilirubinemia and 107 episodes of AP were reported. The treating centers deemed infection (30%) and typhlitis (18%) as the most frequent causes of AP. Six patients developed appendicitis (2%). Patients experiencing concurrent AP and sepsis had a high risk of TRM (36%, n=4). Eighty percent of episodes with hyperbilirubinemia fulfilled the European Society for Bone and Marrow Transplantation criteria for sinusoidal obstruction syndrome. In conclusion, abdominal complications were frequent with infection considered the predominate cause. Most patients with hyperbilirubinemia fulfilled the criteria for sinusoidal obstruction syndrome. AML treatment might be associated with appendicitis. Patients suffering from concurrent AP and sepsis had a high risk of TRM indicating that high awareness of abdominal complications is essential to reduce mortality, especially during sepsis.

Place, publisher, year, edition, pages
Ovid Technologies (Wolters Kluwer Health), 2022
Keywords
acute myeloid leukemia, pediatric, typhlitis, appendicitis, sinusoidal obstruction syndrome
National Category
Hematology Pediatrics
Identifiers
urn:nbn:se:uu:diva-480368 (URN)10.1097/MPH.0000000000002281 (DOI)000814334900004 ()34387627 (PubMedID)
Available from: 2022-07-11 Created: 2022-07-11 Last updated: 2022-07-11Bibliographically approved
Sundberg, E., Hoffman, T., Nilsson, A., Pahnke, S., Enblad, G., Kolstad, L., . . . Palle, J. (2022). COVID-19 seroprevalence and clinical picture in Swedish pediatric oncology and hematology patients. Pediatric Blood & Cancer, 69(10), Article ID e29773.
Open this publication in new window or tab >>COVID-19 seroprevalence and clinical picture in Swedish pediatric oncology and hematology patients
Show others...
2022 (English)In: Pediatric Blood & Cancer, ISSN 1545-5009, E-ISSN 1545-5017, Vol. 69, no 10, article id e29773Article in journal (Refereed) Published
Abstract [en]

Background

Children develop symptomatic coronavirus disease 2019 (COVID-19) more rarely than adults upon infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pediatric oncology and hematology patients may be at increased risk of severe COVID-19 due to their underlying disease or treatment. We investigated COVID-19 and seroprevalence of anti-SARS-CoV-2 antibodies, respectively, in a Swedish cohort of pediatric oncology and hematology patients.

Procedure

Patients (n = 136) were recruited between June 2020 and September 2021 at Uppsala University Children's Hospital, Sweden. Up to six consecutive blood samples per patient were analyzed for wild-type anti-S1 IgM and IgG antibodies (including after vaccination, n = 4). Clinical data on COVID-19 (including polymerase chain reaction [PCR] test results) were collected from electronic medical records. A questionnaire was completed at recruitment.

Results

A cumulative seroprevalence (IgM and IgG) of 33% (45/136 patients, 95% confidence interval: 25%–41%) was observed in this patient cohort, of whom 66% (90/136 patients) were under severe immunosuppressive treatment during the study period. Increasing patient age (p = .037) and PCR test results (p < .002) were associated with seropositivity in nonvaccinated cases. Most seropositive, nonvaccinated cases (32/43, 74%) were never PCR-verified for SARS-CoV-2 infection. Of the 13 patients with PCR-verified infection, nine (69%) reported mild disease. A majority (63%) reported continued school attendance during the pandemic.

Conclusions

Swedish pediatric oncology and hematology patients developed antibodies against SARS-CoV-2, despite their diagnosis and/or treatment, and the observed seroprevalence was similar to that in national pediatric outpatients. PCR-verified cases underestimate the true incidence of COVID-19 in this patient cohort.

Place, publisher, year, edition, pages
John Wiley & Sons, 2022
National Category
Pediatrics
Research subject
Pediatrics; Infectious Diseases; Oncology; Immunology
Identifiers
urn:nbn:se:uu:diva-477375 (URN)10.1002/pbc.29773 (DOI)000802133500001 ()35615775 (PubMedID)
Funder
Knut and Alice Wallenberg FoundationInsamlingsstiftelsen Lions Cancerforskningsfond Mellansverige Uppsala-ÖrebroScience for Life Laboratory, SciLifeLab
Available from: 2022-06-16 Created: 2022-06-16 Last updated: 2022-10-19Bibliographically approved
Engvall, M., Karlsson, Y., Kuchinskaya, E., Jörnegren, Å., Mathot, L., Pandzic, T., . . . Baliakas, P. (2022). Familial platelet disorder due to germline exonic deletions in RUNX1: a diagnostic challenge with distinct alterations of the transcript isoform equilibrium. Leukemia and Lymphoma, 63(10), 2311-2320
Open this publication in new window or tab >>Familial platelet disorder due to germline exonic deletions in RUNX1: a diagnostic challenge with distinct alterations of the transcript isoform equilibrium
Show others...
2022 (English)In: Leukemia and Lymphoma, ISSN 1042-8194, E-ISSN 1029-2403, Vol. 63, no 10, p. 2311-2320Article in journal (Refereed) Published
Abstract [en]

Germline pathogenic variants in RUNX1 are associated with familial platelet disorder with predisposition to myeloid malignancies (FPD/MM) with intragenic deletions in RUNX1 accounting for almost 7% of all reported variants. We present two new pedigrees with FPD/MM carrying two different germline RUNX1 intragenic deletions. The aforementioned deletions encompass exons 1-2 and 9-10 respectively, with the exon 9-10 deletion being previously unreported. RNA sequencing of patients carrying the exon 9-10 deletion revealed a fusion with LINC00160 resulting in a change in the 3 ' sequence of RUNX1. Expression analysis of the transcript isoform demonstrated altered RUNX1a/b/c ratios in carriers from both families compared to controls. Our data provide evidence on the impact of intragenic RUNX1 deletions on transcript isoform expression and highlight the importance of routinely performing copy number variant analysis in patients with suspected MM with germline predisposition.

Place, publisher, year, edition, pages
Taylor & Francis Group, 2022
Keywords
RUNX1 deletions, thrombocytopenia, FPD, MM, leukemia
National Category
Hematology
Identifiers
urn:nbn:se:uu:diva-492419 (URN)10.1080/10428194.2022.2067997 (DOI)000792741800001 ()35533071 (PubMedID)
Available from: 2023-01-11 Created: 2023-01-11 Last updated: 2023-01-11Bibliographically approved
Hasle, H., Kline, R. M., Kjeldsen, E., Nik-Abdul-Rashid, N. F., Bhojwani, D., Verboon, J. M., . . . Cantor, A. B. (2022). Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype. Blood, 139(21), 3159-3165
Open this publication in new window or tab >>Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype
Show others...
2022 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 139, no 21, p. 3159-3165Article in journal (Refereed) Published
Abstract [en]

Individuals with Down syndrome are at increased risk of myeloid leukemia in early childhood, which is associated with acquisition of GATA1 mutations that generate a short GATA1 isoform called GATA1s. Germline GATA1s-generating mutations result in congenital anemia in males. We report on 2 unrelated families that harbor germline GATA1s-generating mutations in which several members developed acute megakaryoblastic leukemia in early childhood. All evaluable leukemias had acquired trisomy 21 or tetrasomy 21. The leukemia characteristics overlapped with those of myeloid leukemia associated with Down syndrome, including age of onset at younger than 4 years, unique immunophenotype, complex karyotype, gene expression patterns, and drug sensitivity. These findings demonstrate that the combination of trisomy 21 and GATA1s-generating mutations results in a unique myeloid leukemia independent of whether the GATA1 mutation or trisomy 21 is the primary or secondary event and suggest that there is a unique functional cooperation between GATA1s and trisomy 21 in leukemogenesis. The family histories also indicate that germline GATA1s-generating mutations should be included among those associated with familial predisposition for myelodysplastic syndrome and leukemia.

Place, publisher, year, edition, pages
American Society of HematologyAmerican Society of Hematology, 2022
National Category
Hematology
Identifiers
urn:nbn:se:uu:diva-478824 (URN)10.1182/blood.2021011463 (DOI)000807583600009 ()34758059 (PubMedID)
Available from: 2022-06-27 Created: 2022-06-27 Last updated: 2024-01-15Bibliographically approved
Ranta, S., Broman, L. M., Abrahamsson, J., Karlsson, L., Noren-Nyström, U., Palle, J., . . . Harila-Saari, A. (2022). High need for intensive care in paediatric acute myeloid leukaemia: A population-based study. Acta Paediatrica, 111(11), 2235-2241
Open this publication in new window or tab >>High need for intensive care in paediatric acute myeloid leukaemia: A population-based study
Show others...
2022 (English)In: Acta Paediatrica, ISSN 0803-5253, E-ISSN 1651-2227, Vol. 111, no 11, p. 2235-2241Article in journal (Refereed) Published
Abstract [en]

Aim Risk of treatment-related life-threatening toxicity is high in childhood acute myeloid leukaemia (AML), and access to intensive care units (ICU) is crucial. We explored the ICU admission rate and outcome after intensive care in childhood AML in Sweden. Methods Patients diagnosed between 2008 and 2016 were identified from the Swedish Childhood Cancer Registry (SCCR), a national quality registry. Data from SCCR was cross-referenced with clinical questionnaire data from paediatric oncology centers and the Swedish Intensive Care Registry (SIR), another national quality registry. Results According to combined data, 46% of the children (58/126) were admitted to ICU, 17% (21/126) within 1 month from diagnosis. Overall, ICU mortality per admission was 12% and 6% during first-line treatment. There was a discrepancy between admission rate from the clinical questionnaires and SCCR (29%; 36/126 children) and SIR (44%; 55/126) All deaths during first-line treatment occurred at or after ICU care. Conclusion Although admission rate under AML treatment was high, the treatment-related mortality under first-line treatment was low. No child died under first-line treatment without admission to ICU, suggesting good availability. The discrepancy between the two registries, SCCR and SIR, highlights the need for future validation of registry data.

Place, publisher, year, edition, pages
John Wiley & Sons, 2022
Keywords
AML, children, incidence, intensive care
National Category
Pediatrics
Identifiers
urn:nbn:se:uu:diva-494010 (URN)10.1111/apa.16497 (DOI)000832845900001 ()35869573 (PubMedID)
Funder
Swedish Childhood Cancer Foundation, TJ2019-0048
Available from: 2023-01-13 Created: 2023-01-13 Last updated: 2023-01-13Bibliographically approved
Sundberg, E., Georgantzi, K., Langenskiöld, C., Król, L., Nilsson, F., Vogt, H., . . . Nilsson, A. (2022). Low numbers of COVID-19 in Swedish pediatric oncology patients during the first pandemic year despite an open society. Pediatric Blood & Cancer, 69(10), Article ID 29750.
Open this publication in new window or tab >>Low numbers of COVID-19 in Swedish pediatric oncology patients during the first pandemic year despite an open society
Show others...
2022 (English)In: Pediatric Blood & Cancer, ISSN 1545-5009, E-ISSN 1545-5017, Vol. 69, no 10, article id 29750Article in journal (Refereed) Published
Abstract [en]

Background Sweden adopted a different strategy than many other countries to combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and kept most schools open. Initial reports from China suggested that coronavirus disease 2019 (COVID-19) was milder in children compared to adults, but there was a lack of data from immunocompromised children. Therefore, we investigated the rate of verified SARS-CoV-2 infections in our Swedish pediatric oncology patients.

Procedure This was a multicenter retrospective study. A questionnaire including patient data as well as SARS-CoV-2 data was sent to the six Swedish childhood cancer centers in May 2021.

Results During the first pandemic year, 49 patients were identified as SARS-CoV-2 positive, and 22 (45%) children were hospitalized with COVID-19. Two children needed intensive care, but no COVID-19-related deaths were reported. Most patients (n = 36, 73%) were on active chemotherapy treatment and 23 children (49%) attended school or daycare at least part-time. Half of the SARS-CoV-2-positive patients experienced a delay in cancer treatment.

Conclusions Despite the rapid spread of SARS-CoV-2 in Sweden, without a strict lockdown of the society, the number of nationally reported pediatric oncology patients with polymerase chain reaction (PCR)-verified infection was low, and the majority of children had mild disease. Our data show that treatment interruptions occurred frequently and this should clearly be avoided for the coming years.

Place, publisher, year, edition, pages
John Wiley & Sons, 2022
Keywords
COVID-19, hematology, oncology, pediatrics, SARS-CoV-2
National Category
Pediatrics
Research subject
Pediatrics; Immunology; Infectious Diseases; Oncology
Identifiers
urn:nbn:se:uu:diva-477377 (URN)10.1002/pbc.29750 (DOI)000788450800001 ()35484955 (PubMedID)
Funder
Swedish Childhood Cancer Foundation, KP2021-0034Swedish Childhood Cancer Foundation, 2020-0008
Available from: 2022-06-16 Created: 2022-06-16 Last updated: 2024-01-15Bibliographically approved
Arad-Cohen, N., Zeller, B., Abrahamsson, J., Fernandez Navarro, J. M., Cheuk, D., Palmu, S., . . . Kaspers, G. J. L. (2022). Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium. Expert Review of Anticancer Therapy, 22(11), 1183-1196
Open this publication in new window or tab >>Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium
Show others...
2022 (English)In: Expert Review of Anticancer Therapy, ISSN 1473-7140, E-ISSN 1744-8328, Vol. 22, no 11, p. 1183-1196Article, review/survey (Refereed) Published
Abstract [en]

Introduction Pediatric acute myeloid leukemia (AML) is the second most common type of pediatric leukemia. Patients with AML are at high risk for several complications such as infections, typhlitis, and acute and long-term cardiotoxicity. Despite this knowledge, there are no definite supportive care guidelines as to what the best approach is to manage or prevent these complications. Area covered The NOPHO-DB-SHIP (Nordic-Dutch-Belgian-Spain-Hong-Kong-Israel-Portugal) consortium, in preparation for a new trial in pediatric AML patients, had dedicated meetings for supportive care. In this review, the authors discuss the available data and outline recommendations for the management of children and adolescents with AML with an emphasis on hyperleukocytosis, tumor lysis syndrome, coagulation abnormalities and bleeding, infection, typhlitis, malnutrition, cardiotoxicity, and fertility preservation. Expert opinion Improved supportive care has significantly contributed to increased cure rates. Recommendations on supportive care are an essential part of treatment for this highly susceptible population and will further improve their outcome.

Place, publisher, year, edition, pages
Taylor & Francis Group, 2022
Keywords
Acute myeloid leukemia, cardiotoxicity, children, coagulation, hyperleukocytosis, infection, supportive care, tumor lysis syndrome, typhlitis
National Category
Hematology Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-496031 (URN)10.1080/14737140.2022.2131544 (DOI)000875565600001 ()36191604 (PubMedID)
Available from: 2023-02-07 Created: 2023-02-07 Last updated: 2023-02-07Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0001-7431-2865

Search in DiVA

Show all publications